US20190343836A1 - Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor - Google Patents

Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor Download PDF

Info

Publication number
US20190343836A1
US20190343836A1 US16/475,982 US201816475982A US2019343836A1 US 20190343836 A1 US20190343836 A1 US 20190343836A1 US 201816475982 A US201816475982 A US 201816475982A US 2019343836 A1 US2019343836 A1 US 2019343836A1
Authority
US
United States
Prior art keywords
amino
methyl
decan
azaspiro
thio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/475,982
Other languages
English (en)
Inventor
Leila DARDAEI ALGHALANDIS
Jeffrey Adam ENGELMAN
Huaixiang Hao
Matthew J. LaMarche
Fang Li
Hui-Qin Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
General Hospital Corp
Original Assignee
Novartis AG
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, General Hospital Corp filed Critical Novartis AG
Priority to US16/475,982 priority Critical patent/US20190343836A1/en
Assigned to NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. reassignment NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HAO, HUAIXIANG, LAMARCHE, MATTHEW J., WANG, Hui-qin
Assigned to NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. reassignment NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LI, FANG
Assigned to NOVARTIS AG reassignment NOVARTIS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.
Assigned to THE GENERAL HOSPITAL CORPORATION reassignment THE GENERAL HOSPITAL CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ALGHALANDIS, LEILA DARDAEI
Assigned to THE GENERAL HOSPITAL CORPORATION reassignment THE GENERAL HOSPITAL CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ENGELMAN, Jeffrey Adam
Publication of US20190343836A1 publication Critical patent/US20190343836A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • FIG. 2 Plot of the growth inhibition of MGH049 tumor model with ceritinb, Compound No. 1, or the combination of ceritinib and Compound No. 1.
  • the MGH049 cell line was implanted into the flanks of nude mice. Animals were randomized into 4 groups when the average tumor volume was 200-300 mm 3 and received vehicle, ceritinib (20 mg/kg), Compound No. 1 (75 mg/kg) or both inhibitors in combination. Tumor dimensions and body weights were measured at the time of randomization and twice weekly thereafter for the study duration. Average tumor volume and SEM are shown as a function of time. Data shows the combination of ceritinib and Compound No. 1 is more effective in the inhibition of tumor growth than either compound alone in vivo.
  • the ALK inhibitor can be for example a compound selected from the group consisting of 5-chloro-N2-[2-isopropoxy-5-methyl-4-(4-piperidinyl)phenyl]-N4-[2-(isopropylsulfonyl)phenyl]-2,4-pyrimidinediamine (ceritinib), (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (lorlatinib; PF-06463922),
  • drug active substance
  • active ingredient active ingredient
  • active agent active agent
  • agent agents that are to be understood as meaning a compound in free form or in the form of a pharmaceutically acceptable salt, in particular compounds specified herein.
  • an ALK inhibitor is also referred to as “combination partner (i)”.
  • SHP2 inhibitor is also referred to as “combination partner (ii)
  • joint therapeutically effective amount means the amount at which the therapeutic agents, when given separately (in a chronologically staggered manner, especially a sequence-specific manner) to a warm-blooded animal, especially to a human to be treated, show a (additive, but preferably synergistic) interaction (joint therapeutic effect). Whether this is the case can be determined inter alia by following the blood levels, showing that both compounds are present in the blood of the human to be treated at least during certain time intervals.
  • a pharmaceutical combination comprising:
  • SHP2 inhibitor is (S)-N-(3-((3-amino-5-(4-amino-2-oxa-8-azaspiro[4.5]decan-8-yl)pyrazin-2-yl)thio)-2-chlorophenyl)-2-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-3-carboxamide.
  • a pharmaceutical composition comprising a pharmaceutical combination of any one of Embodiments 1 to 60 and at least one pharmaceutically acceptable carrier.
  • salt or “salts” is understood to be a salt of an ALK inhibitor and are preferably pharmaceutically acceptable salts.
  • Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
  • Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, and the like. Since a SHP2 inhibitor may include more than one acidic or basic moieties, the SHP2 inhibitor may include mono, di or tri-salts in a single active ingredient.
  • Suitable pharmaceutical compositions for the combination therapy for enteral or parenteral administration are, for example, those in unit dosage forms, such as coated tablets, tablets, capsules or suppositories, or ampoules. If not indicated otherwise, these are prepared in a manner known per se, for example by means of various conventional mixing, comminution, direct compression, granulating, coating, dissolving, lyophilizing processes, or fabrication techniques readily apparent to those skilled in the art. It will be appreciated that the unit content of a combination partner contained in an individual dose of each dosage form need not in itself constitute an effective amount since the necessary effective amount may be reached by administration of a plurality of dosage units, or the therapeutic effect may be achieved only after both combination partners are administered to the subject.
  • a therapeutically effective amount of a SHP2 inhibitor in vivo may range depending on the route of administration, between about 0.05 to about 15 mg per kg body weight per day, preferably about 0.1-5 mg/kg/day, more preferably from about 0.25-3 mg/kg/day, in single or divided doses. For a 70 kg human, this would amount to a preferable dosage range of about 17.5-210 mg per day.
  • each of the combination partners employed in the COMBINATION OF THE INVENTION may vary depending on the particular compound or pharmaceutical composition employed, the mode of administration, the condition being treated, and the severity of the condition being treated.
  • the dosage regimen of the COMBINATION OF THE INVENTION is selected in accordance with a variety of factors including the route of administration and the renal and hepatic function of the patient.
  • a clinician or physician of ordinary skill can readily determine and prescribe the effective amount of the single therapeutic agents required to alleviate, counter or arrest the progress of the condition.
  • each combination partner for treatment of a proliferative disease can be determined empirically for each individual using known methods and will depend upon a variety of factors, including, though not limited to, the degree of advancement of the disease; the age, body weight, general health, gender and diet of the individual; the time and route of administration; and other medications the individual is taking.
  • Frequency of dosage may vary depending on the compound used and the particular condition to be treated or prevented. Patients may generally be monitored for therapeutic effectiveness using assays suitable for the condition being treated or prevented, which will be familiar to those of ordinary skill in the art.
  • a pharmaceutical preparation comprising:
  • the combination of the invention may provide a synergistic therapeutic effect, e.g. with regard to alleviating, delaying progression of or inhibiting the symptoms of proliferative diseases, such as cancer, particularly lung cancer.
  • Certain combinations of the invention may provide an additive effect, e.g. with regard to alleviating, delaying progression of or inhibiting the symptoms of proliferative diseases, such as cancer, particularly lung cancer.
  • Another aspect of the present invention particularly pertains to a pharmaceutical combination
  • a pharmaceutical combination comprising:
  • ALK-positive cancer selected from anaplastic large-cell lymphoma, gastric cancer, breast cancers, oesophageal cancer, colorectal cancer, neuroblastoma, inflammatory myofibroblastic tumor, renal cancer, pancreatic cancer and lung cancer.
  • a method for treating cancer, in a subject in need thereof, comprising the simultaneous or sequential administration to said subject a therapeutically effective amount of:
  • An aspect of the present invention relates to pharmaceutical combinations or pharmaceutical compositions comprising:
  • Embodiment 92 wherein the cancer is an ALK-positive cancer.
  • Embodiment 92 wherein the cancer is an ALK-positive cancer selected from anaplastic large-cell lymphoma, gastric cancer, breast cancers, oesophageal cancer, colorectal cancer, neuroblastoma, inflammatory myofibroblastic tumor, renal cancer, pancreatic cancer and lung cancer.
  • ALK-positive cancer selected from anaplastic large-cell lymphoma, gastric cancer, breast cancers, oesophageal cancer, colorectal cancer, neuroblastoma, inflammatory myofibroblastic tumor, renal cancer, pancreatic cancer and lung cancer.
  • Embodiment 92 wherein the cancer is an ALK-positive cancer resistant to the ALK inhibitor of the pharmaceutical combination.
  • a commercial package comprising the pharmaceutical combination of any one of Embodiments 1 to 60, together with instructions for simultaneous or sequential administration thereof for use in the treatment of cancer.
  • Embodiment 100 wherein the cancer is an ALK-positive cancer resistant to the ALK inhibitor of the pharmaceutical combination.
  • Cell colony formation assays were used to assess cell viability and proliferation after compound treatments.
  • Cells were plated into 6-well tissue culture plates (6 ⁇ 10 5 cells/well) in a total volume of 2 mL. After 24 hours, compounds were added to the plates. At the end points of the assays, cells were fixed, stained with crystal violet and photographed.
  • FIG. 1 shows the photographs obtained from cell colony formation assays with MGH049, MGH045-2A and MGH073-2B cells used to assess the anti-proliferative effect of ceritinib in combination with a SHP2 inhibitor (Compound No. 1).
  • Cells were exposed to ceritinib, Compound No. 1 or the combination for 14 days, and stained with crystal violet.
  • the combination of ALK and SHP2 inhibition led to significant inhibition of cell survival compared with ceritinib alone.
  • Compound No. 1 had no effect on cell growth as a single agent, suggesting that these cell lines are ALK-dependent and signaling via SHP2 functions as a survival pathway or confers resistance to ceritinib.
  • combination of ALK and SHP2 inhibition may either enhance the anti-tumor activity of an ALK inhibitor, particularly ceritinib, and/or overcome ALK inhibitor resistance, particularly ceritinib resistance in ALK-positive cancer, such as NSCLC.
  • MGH049 and MGH045-2A tumor xenograft models were used to evaluate the efficacy of the combination of an ALK inhibitor with a SHP2 inhibitor in vivo. All animal studies were conducted in accordance with the guidelines as published in the Guide for the Care and Use of Laboratory Animals and Novartis International Animal Care and Use Committee (IACUC) regulations and guidelines.
  • the MGH045-2A cells were harvested during exponential growth. Each athymic female nude mouse (Harlan Laboratories, Indianapolis, Ind.) was inoculated subcutaneously in the upper right flank with 5 ⁇ 10 6 NB-1 cells suspended in 0.2 mL cold PBS. The development of MGH049 xenograft tumors comprised 2 steps.
  • FIG. 2 demonstrates that in the MGH049 tumor xenograft model the combination of ceritinib and a SHP2 inhibitor (Compound No. 1) was more effective in the inhibition of tumor growth than either compound alone.
  • FIG. 3 demonstrates that in the MGH045-2A tumor xenograft model the combination of ceritinib and a SHP2 inhibitor (Compound No. 1) was more effective in the inhibition of tumor growth than either compound alone.
  • FIG. 4 demonstrates that in the MGH073-B tumor xenograft model the combination of ceritinib and a SHP2 inhibitor (Compound No. 1) was more effective in the inhibition of tumor growth than either compound alone.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
US16/475,982 2017-01-10 2018-01-08 Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor Abandoned US20190343836A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/475,982 US20190343836A1 (en) 2017-01-10 2018-01-08 Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762444493P 2017-01-10 2017-01-10
US16/475,982 US20190343836A1 (en) 2017-01-10 2018-01-08 Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
PCT/IB2018/050111 WO2018130928A1 (en) 2017-01-10 2018-01-08 Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2018/050111 A-371-Of-International WO2018130928A1 (en) 2017-01-10 2018-01-08 Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/714,996 Continuation US12053470B2 (en) 2017-01-10 2022-04-06 Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor

Publications (1)

Publication Number Publication Date
US20190343836A1 true US20190343836A1 (en) 2019-11-14

Family

ID=61028108

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/475,982 Abandoned US20190343836A1 (en) 2017-01-10 2018-01-08 Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
US17/714,996 Active 2038-02-23 US12053470B2 (en) 2017-01-10 2022-04-06 Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/714,996 Active 2038-02-23 US12053470B2 (en) 2017-01-10 2022-04-06 Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor

Country Status (11)

Country Link
US (2) US20190343836A1 (https=)
EP (1) EP3568204B1 (https=)
JP (2) JP7503380B2 (https=)
KR (1) KR102571130B1 (https=)
CN (1) CN110730678B (https=)
AU (1) AU2018207464B2 (https=)
CA (1) CA3048340A1 (https=)
ES (1) ES2964956T3 (https=)
IL (1) IL267617A (https=)
RU (1) RU2769132C2 (https=)
WO (1) WO2018130928A1 (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10894797B2 (en) 2018-09-18 2021-01-19 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors
WO2022235815A1 (en) * 2021-05-05 2022-11-10 Huabio International, Llc Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors
US11827644B2 (en) 2019-03-04 2023-11-28 Suzhou Genhouse Pharmaceutical Co., Ltd Pyrazine derivative and application thereof in inhibiting SHP2
EP4093406A4 (en) * 2020-01-24 2024-02-28 Taiho Pharmaceutical Co., Ltd. IMPROVEMENT OF THE ANTI-TUMORAL ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NEW ANTI-CANCER DRUGS AGAINST CANCER
US12037345B2 (en) 2018-07-24 2024-07-16 Taiho Pharmaceutical Co., Ltd. Heterobicyclic compounds for inhibiting the activity of SHP2
US12097203B2 (en) 2021-05-05 2024-09-24 Huyabio International, Llc Combination therapies comprising SHP2 inhibitors and PD-1 inhibitors
US12390469B2 (en) 2021-05-05 2025-08-19 Huyabio International, Llc SHP2 inhibitor monotherapy and uses thereof
US12458640B2 (en) 2019-08-20 2025-11-04 Otsuka Pharmaceutical Co., Ltd. Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11466017B2 (en) 2011-03-10 2022-10-11 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
EP3424505A4 (en) 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
AU2017274199B2 (en) 2016-05-31 2021-09-23 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
EA202092441A1 (ru) * 2016-06-07 2021-05-21 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
MX383856B (es) 2016-06-14 2025-03-14 Novartis Ag Compuestos y composiciones para inhibir la actividad de shp2.
KR102598895B1 (ko) 2016-07-12 2023-11-07 레볼루션 메디슨즈, 인크. 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진
MX2019008695A (es) 2017-01-23 2019-09-11 Revolution Medicines Inc Compuestos biciclicos como inhibidores alostericos de shp2.
MX2019008696A (es) 2017-01-23 2019-09-13 Revolution Medicines Inc Compuestos de piridina como inhibidores de shp2 alostericos.
CA3074690A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
WO2019051469A1 (en) 2017-09-11 2019-03-14 Krouzon Pharmaceuticals, Inc. Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2
MX2020003579A (es) * 2017-10-12 2020-07-22 Revolution Medicines Inc Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos.
BR112020009757A2 (pt) 2017-12-15 2020-11-03 Revolution Medicines, Inc. compostos policíclicos como inibidores alostéricos de shp2
NZ766835A (en) 2018-03-02 2023-09-29 Otsuka Pharma Co Ltd Pharmaceutical compounds
SG11202008435SA (en) 2018-03-19 2020-10-29 Taiho Pharmaceutical Co Ltd Pharmaceutical composition including sodium alkyl sulfate
RU2020133727A (ru) 2018-03-21 2022-04-21 Сучжоу Пухе Биофарма Ко., Лтд. Ингибиторы shp2 и их применение
KR102611661B1 (ko) 2018-05-02 2023-12-08 나비레 파르마, 인코퍼레이티드 Ptpn11의 치환된 헤테로사이클릭 억제제
TW202019962A (zh) 2018-07-10 2020-06-01 法商賽諾菲公司 標靶CD38及TGF-β的組合療法
LT3833670T (lt) 2018-08-10 2024-06-25 Navire Pharma, Inc. 6-(4-amino-3-metil-2-oksa-8-azaspiro[4.5]dekan-8-il)-3-(2,3-dichlorfenil)-2-metilpirimidin-4(3h)-ono dariniai ir susiję junginiai kaip ptpn11 (shp2) inhibitoriai, skirti vėžiui gydyti
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
JP2022502385A (ja) 2018-09-29 2022-01-11 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための化合物の製造方法
CA3112322A1 (en) 2018-09-29 2020-04-02 Novartis Ag Manufacture of compounds and compositions for inhibiting the activity of shp2
WO2020072656A1 (en) 2018-10-03 2020-04-09 Gilead Sciences, Inc. Imidozopyrimidine derivatives
CN111153899B (zh) * 2018-11-08 2023-12-01 四川科伦博泰生物医药股份有限公司 一种取代吡啶化合物、其制备方法和用途
CN113272303B (zh) 2018-11-30 2024-09-17 上海拓界生物医药科技有限公司 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
KR20210126653A (ko) * 2019-02-12 2021-10-20 노파르티스 아게 Tno155 및 리보시클립을 포함하는 약제학적 조합물
MX2021009562A (es) * 2019-02-12 2021-09-08 Novartis Ag Combinacion farmaceutica que comprende tno155 y un inhibidor de pd-1.
WO2020165732A1 (en) * 2019-02-12 2020-08-20 Novartis Ag Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
CN113727758A (zh) 2019-03-01 2021-11-30 锐新医药公司 双环杂环基化合物及其用途
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
CA3127361A1 (en) 2019-03-07 2020-09-10 Merck Patent Gmbh Carboxamide-pyrimidine derivatives as shp2 antagonists
CA3127475A1 (en) 2019-04-08 2020-10-15 Merck Patent Gmbh Pyrimidinone derivatives as shp2 antagonists
AU2020306124A1 (en) 2019-06-28 2022-02-03 Tuojie Biotech (Shanghai) Co., Ltd. Pyrimidine five-membered nitrogen heterocyclic derivative, preparation method thereof and pharmaceutical use thereof
US20230010886A1 (en) * 2019-09-23 2023-01-12 Suzhou Puhe BioPharma Co., Ltd. Shp2 inhibitors and uses thereof
CN112724145A (zh) * 2019-10-14 2021-04-30 杭州雷索药业有限公司 用于抑制shp2活性的吡嗪衍生物
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
CN120699039A (zh) 2019-11-04 2025-09-26 锐新医药公司 Ras抑制剂
MX2022005359A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
TW202128688A (zh) 2019-11-08 2021-08-01 美商銳新醫藥公司 雙環雜芳基化合物及其用途
EP4065231A1 (en) 2019-11-27 2022-10-05 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2021110796A1 (en) * 2019-12-04 2021-06-10 Bayer Aktiengesellschaft Inhibitors of shp2
CN113135910A (zh) * 2020-01-19 2021-07-20 北京诺诚健华医药科技有限公司 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用
CN111265529B (zh) * 2020-02-22 2021-07-23 南京大学 蛋白酪氨酸磷酸酶shp2抑制剂在制备治疗银屑病药物中的应用
CN111393459B (zh) * 2020-04-16 2022-07-22 南京安纳康生物科技有限公司 Shp2抑制剂及其用途
JP2023524789A (ja) * 2020-05-08 2023-06-13 ノバルティス アーゲー Ｔｎｏ１５５及びナザルチニブを含む医薬組合せ
US20230218765A1 (en) * 2020-05-19 2023-07-13 The Regents Of The University Of Michigan Small molecule degraders of shp2 protein
WO2021249449A1 (en) * 2020-06-11 2021-12-16 Betta Pharmaceuticals Co., Ltd Shp2 inhibitors, compositions and uses thereof
IL299131A (en) 2020-06-18 2023-02-01 Revolution Medicines Inc Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
EP4169913A4 (en) * 2020-06-22 2024-10-30 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SUBSTITUTED PYRAZINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
CN115916786B (zh) 2020-07-08 2025-10-17 诺华股份有限公司 用于抑制shp2活性的化合物和组合物的制造
MX2023002248A (es) 2020-09-03 2023-05-16 Revolution Medicines Inc Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
MX2023003060A (es) 2020-09-15 2023-04-05 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
WO2022089389A1 (zh) * 2020-10-30 2022-05-05 赣江新区博瑞创新医药有限公司 杂环化合物及其制备方法、药物组合物和应用
CN112194652B (zh) * 2020-11-30 2021-03-05 北京华氏开元医药科技有限公司 4-羟甲基-1h-吲哚类化合物、制备方法及应用
CN112402385B (zh) * 2020-11-30 2022-04-01 北京华氏开元医药科技有限公司 4-羟甲基-1h-吲哚类化合物药物制剂及其制备方法
US20240051956A1 (en) 2020-12-22 2024-02-15 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
CA3217393A1 (en) 2021-05-05 2022-11-10 Elena S. Koltun Ras inhibitors
AU2022268962A1 (en) 2021-05-05 2023-12-14 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
TW202244049A (zh) * 2021-05-12 2022-11-16 大陸商藥雅科技（上海）有限公司 Shp2磷酸酶抑制劑的製備及其應用
CN115594666B (zh) * 2021-07-07 2024-05-31 海创药业股份有限公司 一种磷酸酶降解剂的合成和应用
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
KR20230106506A (ko) * 2022-01-03 2023-07-13 한국생명공학연구원 Cda 억제제를 포함하는 alk 저해제 내성 비소세포폐암 치료용 조성물
TW202342040A (zh) * 2022-02-21 2023-11-01 瑞士商諾華公司 藥物配製物
CN119136806A (zh) 2022-03-08 2024-12-13 锐新医药公司 用于治疗免疫难治性肺癌的方法
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
EP4687905A1 (en) 2023-03-30 2026-02-11 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
KR20260005904A (ko) 2023-04-07 2026-01-12 레볼루션 메디슨즈, 인크. 매크로사이클릭 ras 억제제
CN121263418A (zh) 2023-04-07 2026-01-02 锐新医药公司 大环ras抑制剂
AU2024252105A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
KR20250172857A (ko) 2023-04-14 2025-12-09 레볼루션 메디슨즈, 인크. Ras 억제제의 결정형
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
TW202542151A (zh) 2023-12-22 2025-11-01 美商銳格醫藥有限公司 Ｓｏｓ１抑制劑及其用途
WO2025140560A1 (zh) * 2023-12-28 2025-07-03 轩竹生物科技股份有限公司 间变性淋巴瘤激酶抑制剂的药物组合物及其制备方法
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2567518B1 (fr) 1984-07-11 1987-11-13 Sanofi Sa Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent
EP0257102B1 (en) 1986-02-24 1997-11-19 Mitsui Petrochemical Industries, Ltd. Agents for treating neurophathy
DK169008B1 (da) 1990-06-01 1994-07-25 Holec Lk A S Fremgangsmåde og skærm til afskærmning af en strømtransformer samt strømtransformer med en sådan afskærmning
GB9012316D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
AU4198400A (en) 1999-04-06 2000-10-23 Krenitsky Pharmaceuticals Inc. Neurotrophic thio substituted pyrimidines
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
ATE407678T1 (de) 2001-10-17 2008-09-15 Boehringer Ingelheim Pharma Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
GB0300783D0 (en) 2003-01-14 2003-02-12 Btg Int Ltd Treatment of neurodegenerative conditions
CN1938296A (zh) 2004-04-01 2007-03-28 安斯泰来制药有限公司 作为腺苷拮抗剂的吡嗪衍生物及其制药用途
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
CA2591413A1 (en) 2004-12-16 2006-06-22 Vertex Pharmaceuticals Incorporated Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases
US20090306038A1 (en) 2005-09-13 2009-12-10 Carceller Gonzalez Elena 2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity
EP1999108A1 (en) 2006-03-28 2008-12-10 Takeda Pharmaceutical Company Limited Preparation of (r)-3-aminopiperidine dihydrochloride
US7515405B2 (en) 2006-07-25 2009-04-07 Hewlett-Packard Development Company, L.P. Anti-rotation mechanism for an electronic device
US20090137549A1 (en) 2006-11-09 2009-05-28 Paul John Edward Novel compounds useful for the treatment of degenerative & inflamatory diseases
BRPI0720264B1 (pt) 2006-12-08 2022-03-03 Novartis Ag Compostos e composições como inibidores de proteína cinase
EP2120573A4 (en) 2007-02-12 2011-05-25 Merck Sharp & Dohme piperidine
PE20090188A1 (es) 2007-03-15 2009-03-20 Novartis Ag Compuestos heterociclicos como moduladores de la senda de hedgehog
NZ588830A (en) 2008-04-22 2012-11-30 Portola Pharm Inc Inhibitors of protein kinases
AU2009256574A1 (en) 2008-06-13 2009-12-17 Novartis Ag 2,4'-bipyridinyl compounds as protein kinase D inhibitors useful for the treatment of IA heart failure and cancer
MX2010013876A (es) 2008-06-20 2011-03-04 Metabolex Inc Agonistas de arilo grpr119 y sus usos .
TWI546290B (zh) 2008-06-27 2016-08-21 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
WO2010011666A2 (en) 2008-07-21 2010-01-28 University Of South Florida Indoline scaffold shp-2 inhibitors and cancer treatment method
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
WO2010067987A2 (ko) 2008-12-10 2010-06-17 동화약품주식회사 신규한 2, 6-위치에 치환된 3-니트로피리딘 유도체, 그의 제조방법 및 이를 포함하는 약학 조성물
FR2941696B1 (fr) 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
WO2010121212A2 (en) 2009-04-17 2010-10-21 H. Lee Moffit Cancer Center And Research Institute, Inc. Indoline scaffold shp-2 inhibitors and method of treating cancer
KR101906146B1 (ko) 2009-08-17 2018-10-10 메모리얼 슬로안-케터링 캔서 센터 열 충격 단백질 결합 화합물, 조성물, 및 이의 제조 방법 및 사용 방법
US8673913B2 (en) 2009-11-13 2014-03-18 Case Western Reserve University SHP-2 phosphatase inhibitor
WO2011078143A1 (ja) 2009-12-22 2011-06-30 塩野義製薬株式会社 ピリミジン誘導体およびそれらを含有する医薬組成物
WO2012002577A1 (ja) 2010-06-30 2012-01-05 富士フイルム株式会社 新規なニコチンアミド誘導体またはその塩
JP2013531037A (ja) 2010-07-13 2013-08-01 メルク・シャープ・エンド・ドーム・コーポレイション スピロ環式化合物
BR112013002112B1 (pt) 2010-07-29 2021-04-06 Rigel Pharmaceuticals, Inc. Composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável, ou de uma composição
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
JP5802756B2 (ja) 2010-10-20 2015-11-04 ファイザー・インク スムーズンド受容体モジュレーターとしてのピリジン−２−誘導体
CN103930407B (zh) 2011-09-12 2019-02-26 默克专利有限公司 用作激酶活性调节剂的氨基嘧啶衍生物
WO2013096093A1 (en) 2011-12-21 2013-06-27 Merck Sharp & Dohme Corp. Compounds as dgat-1 inhibitors
EP2855460B1 (en) * 2012-05-23 2017-11-08 Nerviano Medical Sciences S.r.l. Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
CN104540830A (zh) 2012-06-07 2015-04-22 霍夫曼-拉罗奇有限公司 端锚聚合酶的吡唑并嘧啶酮和吡唑并吡啶酮抑制剂
EP2903985A1 (en) 2012-10-03 2015-08-12 Advinus Therapeutics Limited Spirocyclic compounds, compositions and medicinal applications thereof
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
WO2015050344A1 (ko) 2013-10-01 2015-04-09 주식회사 엘지화학 도전성 적층체
WO2015092819A2 (en) 2013-12-21 2015-06-25 Nektar Therapeutics (India) Pvt. Ltd. Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5- amine
EP3086810A2 (en) * 2013-12-23 2016-11-02 Novartis AG Pharmaceutical combinations
JP6523303B2 (ja) 2014-01-17 2019-05-29 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための１−ピリダジン／トリアジン−３−イル−ピペラジン／ピペリジン／ピロリジン誘導体およびその組成物
CN105899493B (zh) 2014-01-17 2019-03-29 诺华股份有限公司 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
SI3137169T1 (sl) 2014-05-01 2022-04-29 Celgene Quanticel Research, Inc. Inhibitorji lizin specifične demetilaze-1
US10174032B2 (en) 2014-05-05 2019-01-08 Signalrx Pharmaceuticals, Inc. Heterocyclic compound classes for signaling modulation
WO2016023404A1 (zh) 2014-08-15 2016-02-18 贵州省中国科学院天然产物化学重点实验室 双苄基异喹啉衍生物、其制备方法及其在肝病的治疗与预防中的用途
CA2955676A1 (en) * 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
US9296721B1 (en) * 2015-02-13 2016-03-29 Yong Xu Method for preparing ALK inhibitor ceritinib
ES2824576T3 (es) * 2015-06-19 2021-05-12 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
ES2741746T3 (es) * 2015-06-19 2020-02-12 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
CN112625028B (zh) 2015-06-19 2024-10-29 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
WO2017156397A1 (en) * 2016-03-11 2017-09-14 Board Of Regents, The University Of Texas Sysytem Heterocyclic inhibitors of ptpn11
MX383856B (es) 2016-06-14 2025-03-14 Novartis Ag Compuestos y composiciones para inhibir la actividad de shp2.
US11529347B2 (en) * 2016-09-22 2022-12-20 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of use thereof
TW202500565A (zh) * 2016-10-24 2025-01-01 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12037345B2 (en) 2018-07-24 2024-07-16 Taiho Pharmaceutical Co., Ltd. Heterobicyclic compounds for inhibiting the activity of SHP2
US12264167B2 (en) 2018-09-18 2025-04-01 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors
US11034705B2 (en) 2018-09-18 2021-06-15 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors
US11459340B2 (en) 2018-09-18 2022-10-04 Nikang Therapeutics, Inc. Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors
US11518772B2 (en) 2018-09-18 2022-12-06 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors
US10894797B2 (en) 2018-09-18 2021-01-19 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors
US11827644B2 (en) 2019-03-04 2023-11-28 Suzhou Genhouse Pharmaceutical Co., Ltd Pyrazine derivative and application thereof in inhibiting SHP2
US12338246B2 (en) 2019-03-04 2025-06-24 Suzhou Genhouse Pharmaceutical Co., Ltd. Pyrazine derivative and application thereof in inhibiting SHP2
US12458640B2 (en) 2019-08-20 2025-11-04 Otsuka Pharmaceutical Co., Ltd. Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors
EP4093406A4 (en) * 2020-01-24 2024-02-28 Taiho Pharmaceutical Co., Ltd. IMPROVEMENT OF THE ANTI-TUMORAL ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NEW ANTI-CANCER DRUGS AGAINST CANCER
US12097203B2 (en) 2021-05-05 2024-09-24 Huyabio International, Llc Combination therapies comprising SHP2 inhibitors and PD-1 inhibitors
US12390469B2 (en) 2021-05-05 2025-08-19 Huyabio International, Llc SHP2 inhibitor monotherapy and uses thereof
WO2022235815A1 (en) * 2021-05-05 2022-11-10 Huabio International, Llc Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors

Also Published As

Publication number Publication date
US12053470B2 (en) 2024-08-06
JP2020504136A (ja) 2020-02-06
KR20190104530A (ko) 2019-09-10
RU2019120986A3 (https=) 2021-03-19
JP2022184886A (ja) 2022-12-13
AU2018207464B2 (en) 2020-05-14
CN110730678A (zh) 2020-01-24
RU2019120986A (ru) 2021-02-12
WO2018130928A1 (en) 2018-07-19
CN110730678B (zh) 2022-07-15
US20220241277A1 (en) 2022-08-04
EP3568204B1 (en) 2023-08-30
CA3048340A1 (en) 2018-07-19
RU2769132C2 (ru) 2022-03-28
AU2018207464A1 (en) 2019-06-20
JP7503380B2 (ja) 2024-06-20
KR102571130B1 (ko) 2023-08-28
EP3568204A1 (en) 2019-11-20
IL267617A (en) 2019-08-29
ES2964956T3 (es) 2024-04-10

Similar Documents

Publication Publication Date Title
US12053470B2 (en) Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor
US10130629B2 (en) Pharmaceutical combinations
US12264155B2 (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors
US12435090B2 (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use
US20230151014A1 (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use
AU2014372166B2 (en) Pharmaceutical combinations
US20220185809A1 (en) Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors
US20110065712A1 (en) Tricyclic compounds and pharmaceutical uses thereof
UA125216C2 (uk) Комбінована терапія
US20140142129A1 (en) Methods of treating a disease or disorder associated with bruton's tyrosine kinase
WO2021100677A1 (ja) 併用医薬
RU2445960C2 (ru) Применение производных пиримидиламинобензамида для лечения системного мастоцитоза
HK40010171A (en) Pharmaceutical combination comprising an alk inhibitor and an shp2 inhibitor
HK40010171B (en) Pharmaceutical combination comprising an alk inhibitor and an shp2 inhibitor
HK40016954A (en) Combinations of akt and mek inhibitor compounds, and methods of use

Legal Events

Date Code Title Description
AS Assignment

Owner name: THE GENERAL HOSPITAL CORPORATION, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALGHALANDIS, LEILA DARDAEI;REEL/FRAME:050962/0798

Effective date: 20171222

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.;REEL/FRAME:050962/0793

Effective date: 20171211

Owner name: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.,

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HAO, HUAIXIANG;LAMARCHE, MATTHEW J.;WANG, HUI-QIN;REEL/FRAME:050962/0760

Effective date: 20171205

Owner name: THE GENERAL HOSPITAL CORPORATION, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ENGELMAN, JEFFREY ADAM;REEL/FRAME:050962/0804

Effective date: 20181206

Owner name: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.,

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LI, FANG;REEL/FRAME:050962/0779

Effective date: 20170126

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION